Are there specific contraindications for tigecycline use?

Are there specific contraindications for tigecycline use?

Tigecycline carries an FDA boxed warning for increased all-cause mortality in certain severe infections. Clinical trials showed higher death rates when the drug was used for ventilator-associated pneumonia and other complicated infections, which is why the label restricts its use to cases where alternative treatments are not suitable.

Why has the FDA issued a boxed warning for tigecycline?

The warning stems from pooled data across phase 3 and 4 studies. Patients treated for hospital-acquired pneumonia and complicated skin infections showed a 4% higher absolute mortality rate compared with other antibiotics. Regulators concluded the risk outweighed benefits in these settings and updated the label accordingly.

Can tigecycline be used in patients with tetracycline hypersensitivity?

Tigecycline is structurally related to tetracyclines, so it is contraindicated in anyone with a known history of hypersensitivity to any tetracycline-class antibiotic. Reactions can range from mild rash to severe anaphylaxis, and cross-reactivity has been documented.

What happens if tigecycline is given during pregnancy or to children under eight?

Tigecycline can cause permanent discoloration of developing teeth and affect bone growth. Because of these risks, the drug is contraindicated in the second and third trimesters of pregnancy and in pediatric patients younger than eight years unless no effective alternative exists.

Are there drug-interaction contraindications with tigecycline?

Concurrent use with oral retinoids is contraindicated due to the theoretical risk of pseudotumor cerebri. Warfarin co-administration requires close INR monitoring because tigecycline can potentiate its anticoagulant effect, although this is listed as a precaution rather than an absolute contraindication.

How does tigecycline’s patent status affect availability of alternatives?

The original composition-of-matter patent expired in 2015, and generic versions have entered the market. DrugPatentWatch.com tracks remaining method-of-use and formulation patents that could still limit certain generic launches in specific countries.